Scientists engaged in medical research have found that blocking an active gene in liver cancer cells can actually halt the process of chemotherapy resistance thereby increasing the chances of survival. A synthetic molecule designed by a team of scientists has been found to stop the activation of such oncogenes. The cancerous liver cells can then respond to the chemotherapy.

The oncogene STAT3 when blocked can impair the protective functions of a particular protein  making the liver cells respond to treatment by chemotherapy.

The researchers are now anticipating that the successful creation of the synthetic molecule based drug will help the patients overcome cancer. The clinical tests and animal experimentation are yet to be completed.

The molecule known as LLL12 has been used to block STAT3 successfully thereby killing of the cancerous cells in breast and pancreatic cancer as well.

The senior author of the study, Jiayuh Lin, stated that an intravenous drug based on this particular molecule can be manufactured easily. It would be inexpensive as well. Lin also serves as the associate professor of pediatrics at the Ohio State University.

The researchers have also found evidence of STAT3 blockage by LLL12 having a downstream effect where it can successfully block other cancer inducing STAT3 regulated genes as well.  This particular molecule is currently believed to have tremendous potential in curing cancer.

The team of scientists working on the creation of LLL12 was led by Jiayuh Lin and reported their success earlier this year. The procedure of designing the molecule included the use of powerful computers as well as various computational methods.

The results of the study can be found in the most recent issue of the Journal of Biological Chemistry.